Last reviewed · How we verify
Coly-Mycin M (COLISTIMETHATE SODIUM)
Coly-Mycin M (generic name: COLISTIMETHATE SODIUM) is a Polymyxin-class Antibacterial drug developed by Ph Health. It is currently FDA-approved (first approved 1970) for Enterobacter Infection, Infection due to Escherichia coli, Klebsiella Infections.
Coly-Mycin M is an intravenous antibiotic used to treat various bacterial infections, including osteomyelitis and gram-negative bacterial infections. It works by inhibiting the cell membrane, a mechanism that disrupts bacterial cell function.
At a glance
| Generic name | COLISTIMETHATE SODIUM |
|---|---|
| Sponsor | Ph Health |
| Drug class | Polymyxin-class Antibacterial |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1970 |
Approved indications
- Enterobacter Infection
- Infection due to Escherichia coli
- Klebsiella Infections
- Pseudomonas Aeruginosa Infections
- Pseudomonas Respiratory Tract Infection in Cystic Fibrosis
Common side effects
- seizures
- nephrotoxicity
- anaphylaxis
- apnea
- respiratory distress
- decreased urine output
- decreased creatinine clearance
- elevated creatinine
- increased blood urea nitrogen (BUN)
- generalized itching
- urticaria
- rash
Drug interactions
- aminoglycosides
- polymyxin
- curariform muscle relaxants (e.g., tubocurarine)
- ether
- succinylcholine
- gallamine
- decamethonium
- sodium citrate
- sodium cephalothin
Key clinical trials
- Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2,PHASE3)
- Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis (PHASE2)
- Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial (NA)
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
- Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline (PHASE4)
- Comparing Tigecycline Vs. Colistimethate in CNS Infections
- Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection (PHASE4)
- Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coly-Mycin M CI brief — competitive landscape report
- Coly-Mycin M updates RSS · CI watch RSS
- Ph Health portfolio CI
Frequently asked questions about Coly-Mycin M
What is Coly-Mycin M?
What is Coly-Mycin M used for?
Who makes Coly-Mycin M?
What is the generic name of Coly-Mycin M?
What drug class is Coly-Mycin M in?
When was Coly-Mycin M approved?
What development phase is Coly-Mycin M in?
What are the side effects of Coly-Mycin M?
Related
- Drug class: All Polymyxin-class Antibacterial drugs
- Manufacturer: Ph Health — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Enterobacter Infection
- Indication: Drugs for Infection due to Escherichia coli
- Indication: Drugs for Klebsiella Infections
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing